Jen Psaki reacts to the inspiring story of medical school student Shay Taylor-Allen, who’s returning to the hospital where she worked as a janitor, now as a doctor. MS NOW: My Source for News, Opinion, and the World. » Subscribe to MS NOW: https://www.youtube.com/@msnow MS NOW is the go-to destination for domestic and international breaking news, and best-in-class opinion journalism. For more context and news coverage of the most important stories of our day click here: https://www.ms.now/ ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Picard Medical, Inc. regarding a securities class action lawsuit, highlighting allegations of fraudulent activities and misleading statements made by the company during a specified class period [1][2]. Group 1: Allegations - The lawsuit alleges that during the class period from September 2, 2025, to October 31, 2025, Picard Medical was involved in a fraudulent stock promotion scheme that included misinformation spread via social media and impersonation of financial professionals [2]. - It is claimed that insiders and affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures allegedly omitted critical information regarding false rumors and artificial trading activity that influenced the stock price [2]. - As a result of these actions, the positive statements made by the defendants about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Class Action Details - The deadline for shareholders to register for the class action lawsuit is April 3, 2026, and registration is encouraged to ensure participation in any potential recovery [3]. - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case's progress [3]. - There is no cost or obligation for shareholders to participate in the lawsuit [3]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit, fraud, and illegal business practices [4]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [4]. - The firm seeks recovery for investors affected by misleading statements or omissions that led to artificial inflation of stock prices [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Picard Medical, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Picard Medical securities between September 2, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Allegations Against Picard Medical - The lawsuit alleges that Picard Medical's defendants made materially false and misleading statements and failed to disclose adverse facts about the company's operations and securities trading [5]. - Specific allegations include involvement in a fraudulent stock promotion scheme, insider trading through offshore accounts, and misleading public statements regarding the company's business prospects [5].

Core Viewpoint - A class action securities lawsuit has been filed against Picard Medical, Inc. for alleged securities fraud affecting investors between September 2, 2025, and October 31, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonation of financial professionals [2]. - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The complaint states that Picard's public statements and risk disclosures failed to mention the false rumors and artificial trading activity that influenced the stock price [2]. - As a result of these actions, the defendants' positive statements regarding the Company's business and prospects were misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Picard Medical during the specified timeframe have until April 3, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Insights - Solventum Corporation (SOLV) is positioned for growth due to strong demand across its business segments, bolstered by investments in innovation, R&D, and digital capabilities [1] - The company reported a solid performance in Q4 2025 and is optimistic about its restructuring program contributing to future growth, despite concerns over tariffs and rising raw material costs [1][7] Financial Performance - Over the past six months, SOLV shares have decreased by 9%, while the industry grew by 0.1% and the S&P 500 rose by 1.6% [2] - The company has a market capitalization of $11.9 billion and projects a 4.3% earnings growth for 2026, maintaining strong performance [2] - SOLV has consistently surpassed earnings estimates, with an average surprise of 12.4% over the last four quarters [2] Growth Drivers - Solventum identified five key growth drivers expected to contribute over 80% of future growth, focusing on areas with strong brands and clinical differentiation [5] - In MedSurg, opportunities include negative pressure wound therapy and IV site management, with products like Prevena and Tegaderm CHG driving demand [5][6] - The company plans around 20 new product launches in the next two years, with growth in Dental and Health Information Systems also anticipated [6] Restructuring and Cost Savings - Solventum's "Transform for the Future" program aims for approximately $500 million in cost savings through operational efficiencies, with benefits starting in 2026 [8] - The previous restructuring program, Solventum Way, successfully delivered $125 million in annualized savings [8] Recent Developments - SOLV reported strong Q4 results, with earnings and sales exceeding estimates across key segments, supported by effective commercial restructuring [9] - The company completed its first acquisition of Acera Surgical, expanding its MedSurg portfolio [10] Challenges - Tariffs are a structural headwind, with an estimated $100-$120 million impact expected in 2026, despite efforts to expand operating margins [11] - A potential increase in raw material costs from a long-term supply agreement with 3M could create a 100-basis-point margin headwind [12] Estimate Revisions - There has been a positive estimate revision trend for 2026, with the Zacks Consensus Estimate for EPS increasing by 6 cents to $6.43 [13] - The first-quarter revenue estimate is pegged at $1.97 billion, indicating a 4.6% decline from the previous year [13]

Core Viewpoint - Capricor Therapeutics Inc is facing significant financial challenges but is optimistic about its future due to ongoing clinical developments and a favorable consensus price target from analysts [4][6]. Financial Performance - The company is preparing to release its quarterly earnings on March 18, 2026, with an estimated earnings per share (EPS) of -$0.51 and projected revenue of $525,000 [1][6]. - Capricor's financial metrics indicate severe difficulties, including a negative return on equity of -99.57% and a return on assets of -76.16% [2][6]. - The company reported a quarterly loss of 62 cents per share, which is worse than the anticipated 54-cent loss, and revenue dropped to zero from $11.1 million the previous year [5]. Debt and Equity - Despite its financial struggles, Capricor maintains a low debt-to-equity ratio of 0.17, suggesting manageable debt levels [2][6]. Market Outlook - Analysts have a consensus price target of $46.09 for Capricor, indicating a potential upside of 51.12% [4][6]. - The company's cash balance of approximately $318 million is expected to sustain operations through 2027, providing a buffer for ongoing developments [4]. Clinical Developments - Capricor is making progress in its clinical developments, particularly with the FDA's review of their Biologics License Application for Deramiocel and the successful HOPE-3 Phase 3 trial [4][5].

Core Points - Holzer & Holzer, LLC is reminding investors of the deadlines to seek lead plaintiff status in class action lawsuits against Picard Medical, Plug Power, and Richtech Robotics [1][2][3] - The lawsuits allege that the companies made materially false and/or misleading statements or failed to disclose material facts during specific time periods [1][2][3] Company Summaries Picard Medical, Inc. (PMI) - The lawsuit alleges false or misleading statements regarding a fraudulent stock promotion scheme between September 2, 2025, and October 31, 2025 [1] - Investors who purchased shares during this period and suffered losses are encouraged to contact Holzer & Holzer for legal rights [1] Plug Power Inc. (PLUG) - The lawsuit claims that the company made false or misleading statements about the availability of funds from the Department of Energy Loan between January 17, 2025, and November 13, 2025 [2] - Affected investors are advised to reach out to Holzer & Holzer for assistance [2] Richtech Robotics Inc. (RR) - The lawsuit against Richtech alleges misleading statements regarding its relationship with Microsoft between January 27, 2026, and January 29, 2026 [3] - Investors who incurred losses during this timeframe are encouraged to discuss their legal options with Holzer & Holzer [3] Legal Firm Overview - Holzer & Holzer, LLC is recognized as a top-rated securities litigation law firm and has been involved in recovering significant amounts for shareholders affected by corporate misconduct [4] - The firm has a history of representing shareholders in class action and derivative litigation since its founding in 2000 [4]

Core Viewpoint - A class action securities lawsuit has been filed against Picard Medical, Inc. for alleged securities fraud affecting investors between September 2, 2025, and October 31, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Picard Medical was involved in a fraudulent stock promotion scheme that utilized social media misinformation and impersonation of financial professionals [2]. - It is alleged that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The complaint states that Picard's public statements and risk disclosures failed to mention the false rumors and artificial trading activity that influenced the stock price [2]. - As a result of these actions, the defendants' positive statements regarding the Company's business and prospects were deemed materially misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses in Picard Medical, Inc. during the specified timeframe have until April 3, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

分组1 - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market over the next 30 days, based on value, growth, and momentum [2][3] 分组2 - The Value Score identifies stocks that are undervalued based on financial ratios such as P/E and Price/Sales, appealing to value investors [3] - The Growth Score focuses on a company's financial health and future growth potential, analyzing projected and historical earnings and cash flow [4] - The Momentum Score assists investors in capitalizing on price trends, using metrics like recent price changes and earnings estimate revisions [5] 分组3 - The VGM Score combines the three Style Scores, providing a comprehensive rating that highlights stocks with attractive value, strong growth forecasts, and positive momentum [6] - The Zacks Rank, a proprietary stock-rating model, utilizes earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks historically yielding an average annual return of +23.86% since 1988 [7][9] 分组4 - Centene Corporation is a diversified healthcare company focused on government-sponsored healthcare programs, serving under-insured and uninsured individuals [11] - Centene has a Zacks Rank of 3 (Hold) and a VGM Score of A, indicating a solid position in the market [11] - The company has a Momentum Style Score of A, with shares increasing by 13.5% over the past four weeks, and upward revisions in earnings estimates for fiscal 2026 [12]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Picard Medical, Inc. regarding a class action lawsuit due to allegations of misleading statements and fraudulent activities during a specified class period [1]. Group 1: Allegations - The complaint alleges that during the class period from September 2, 2025, to October 31, 2025, Picard Medical was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [3]. - It is claimed that insiders and affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [3]. - The public statements and risk disclosures made by Picard Medical allegedly omitted critical information regarding false rumors and artificial trading activity that influenced the stock price [3]. - As a result of these actions, the defendants' positive statements about the company's business and prospects were deemed materially misleading and lacked a reasonable basis [3]. Group 2: Class Action Details - Shareholders who purchased shares of PMI during the specified class period are encouraged to register for the class action, with a deadline set for April 3, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions that led to artificial stock price inflation [5].